Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy

[1] Liontos M(2016)DNA damage, tumor mutational load and their impact on immune responses against cancer Ann. Transl. Med. 4 264-704

[2] Anastasiou I(2008)PD-1 and its ligands in tolerance and immunity Annu. Rev. Immunol. 26 677-264

[3] Bamias A(2012)The blockade of immune checkpoints in cancer immunotherapy Nat. Rev. Cancer 12 252-135

[4] Dimopoulos MA(2015)Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N. Engl. J. Med. 373 123-1639

[5] Keir ME(2015)Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N. Engl. J. Med. 373 1627-2012

[6] Butte MJ(2015)Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer J. Clin. Oncol. 33 2004-1448

[7] Freeman GJ(2018)Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab Nat. Med. 24 1441-2104

[8] Sharpe AH(2018)Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden N. Engl. J. Med. 378 2093-2028

[9] Pardoll DM(2015)Pembrolizumab for the treatment of non-small-cell lung cancer N. Engl. J. Med. 372 2018-1833

[10] Brahmer J(2016)Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer N. Engl. J. Med. 375 1823-222

[1] Liontos M(2016)DNA damage, tumor mutational load and their impact on immune responses against cancer Ann. Transl. Med. 4 264-704

[2] Anastasiou I(2008)PD-1 and its ligands in tolerance and immunity Annu. Rev. Immunol. 26 677-264

[3] Bamias A(2012)The blockade of immune checkpoints in cancer immunotherapy Nat. Rev. Cancer 12 252-135

[4] Dimopoulos MA(2015)Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N. Engl. J. Med. 373 123-1639

[5] Keir ME(2015)Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N. Engl. J. Med. 373 1627-2012

[6] Butte MJ(2015)Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer J. Clin. Oncol. 33 2004-1448

[7] Freeman GJ(2018)Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab Nat. Med. 24 1441-2104

[8] Sharpe AH(2018)Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden N. Engl. J. Med. 378 2093-2028

[9] Pardoll DM(2015)Pembrolizumab for the treatment of non-small-cell lung cancer N. Engl. J. Med. 372 2018-1833

[10] Brahmer J(2016)Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer N. Engl. J. Med. 375 1823-222